Division to Honor 25-Year Members and Hall of Fame Inductees in San Francisco

The Executive Committee of the Division of Medicinal Chemistry is pleased to announce two new membership recognition programs that will kick off at the San Francisco ACS meeting. 836 medicinal chemists with 25 or more years of Division membership will be recognized at a reception on Wednesday, September 13, 2006 at 5 PM, in room 252/254 of the Moscone Convention Center. Each 25-year member who attends the reception will receive a commemorative Waterman pen. In addition, three individuals will be inducted into the Medicinal Chemistry Hall of Fame to recognize their contributions to the Division and to the discipline of medicinal chemistry. Three scientists will be inducted into the Hall of Fame each calendar year and recognized at a reception at the Fall national meeting of the ACS. Awardees should be members of the Division who have made an overall outstanding contribution to medicinal chemistry through a combination of research, teaching and service, but whose efforts in any of these individual categories does not qualify them for one of the national Division awards. Recipients of the Smissman, Division of Medicinal Chemistry and Burger awards are automatically added to the Hall of Fame roster. For more information on this year’s inductees, see page 6 of this Newsletter.

Division Archives Available On-line

Division newsletters, scientific programs and abstract books are now archived online. Past abstract books dating to 2002 are also available. These documents can be downloaded in .pdf format through the Division WWW page:

http://www.acsmedchem.org

Final Program for the San Francisco ACS Meeting (September 10-14, 2006)

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUN</td>
<td>AM</td>
<td>Telomerase</td>
</tr>
<tr>
<td>SUN</td>
<td>AM</td>
<td>General Oral Session I</td>
</tr>
<tr>
<td>SUN</td>
<td>PM</td>
<td>Small Molecules and Apoptosis</td>
</tr>
<tr>
<td>SUN</td>
<td>EVE</td>
<td>Poster Session I and Social Hour</td>
</tr>
<tr>
<td>MON</td>
<td>AM</td>
<td>Designing Multiple Ligands</td>
</tr>
<tr>
<td>MON</td>
<td>AM</td>
<td>Hepatitis C</td>
</tr>
<tr>
<td>MON</td>
<td>PM</td>
<td>Reverse Pharmacology</td>
</tr>
<tr>
<td>TUES</td>
<td>AM</td>
<td>Award Symposium</td>
</tr>
<tr>
<td>TUES</td>
<td>PM</td>
<td>γ- and β-secretase</td>
</tr>
<tr>
<td>TUES</td>
<td>PM</td>
<td>General Oral Session II</td>
</tr>
<tr>
<td>WED</td>
<td>AM</td>
<td>Neuropeptide GPCRs</td>
</tr>
<tr>
<td>WED</td>
<td>AM</td>
<td>Parallel Medicinal Chemistry</td>
</tr>
<tr>
<td>WED</td>
<td>PM</td>
<td>Antag of TRP Channels/vannillloid Receptor</td>
</tr>
<tr>
<td>WED</td>
<td>PM</td>
<td>Medchem &amp; rare diseases</td>
</tr>
<tr>
<td>WED</td>
<td>EVE</td>
<td>Poster Session II</td>
</tr>
<tr>
<td>THURS</td>
<td>AM</td>
<td>General Oral Session III</td>
</tr>
<tr>
<td>THURS</td>
<td>PM</td>
<td>General Oral Session IV</td>
</tr>
</tbody>
</table>

Preliminary Program for the Chicago ACS Meeting (March 25-29, 2007)

<table>
<thead>
<tr>
<th>OASYS opens Aug. 28, closes Nov. 22, 2006</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUN</td>
</tr>
<tr>
<td>SUN</td>
</tr>
<tr>
<td>SUN</td>
</tr>
<tr>
<td>SUN</td>
</tr>
<tr>
<td>MON</td>
</tr>
<tr>
<td>MON</td>
</tr>
<tr>
<td>MON</td>
</tr>
<tr>
<td>TUES</td>
</tr>
<tr>
<td>TUES</td>
</tr>
<tr>
<td>TUES</td>
</tr>
<tr>
<td>WED</td>
</tr>
<tr>
<td>WED</td>
</tr>
<tr>
<td>WED</td>
</tr>
<tr>
<td>WED</td>
</tr>
<tr>
<td>WED</td>
</tr>
<tr>
<td>THURS</td>
</tr>
<tr>
<td>THURS</td>
</tr>
</tbody>
</table>
Division Co-Sponsors Percy Julian Symposium

The Division is pleased to co-sponsor “Dr. Percy L. Julian: “Scientist, Humanist, Educator, Entrepreneur, and Inspirational Trailblazer,” A Presidential Event” at the San Francisco ACS meeting. The symposium will be held on Monday, September 11, 2006 from 8:30 – 11:30 am and 2:00 – 5:00 pm, and will feature excerpts from the upcoming Nova film biography “Forgotten Genius”, which will be shown on Tuesday, February 6th, 2007 at 8 p.m. during the first week of Black History Month. The room for this symposium has not yet been announced, but the location will be available at the meeting in the program booklet, or through the ACS homepage prior to the meeting.

Division Travel Grants

The Division of Medicinal Chemistry makes 14 grants of $600 available annually to aid young chemists in presenting papers at the ACS National Meetings. Applicants must be ACS members (student or affiliate) and not have previously received a travel award. Each University department can have only one awardee. Application deadlines are the same as the abstract deadline for each meeting. In order of priority, the following individuals will be considered for awards: Graduate Student, Postdoctoral Fellow, individual with less than five years post-Ph.D. experience. The scientific merit of the paper to be presented will also be considered. Send applications to:

David P. Rotella, Ph.D.
Wyeth Research
CN 8000
Princeton NJ, 08543
Phone: 732-274-4504
rotelld@wyeth.com

Awardees will be notified in sufficient time so that they can pre-register for the meeting. Awards are made at the Division business meeting, which is held at each national meeting immediately before the Sunday night poster session and mixer. Contact info and a complete application for the travel award appears on page 3.

CALL FOR PAPERS
233rd NATIONAL ACS MEETING
Chicago, IL
(March 25-29, 2007)

The OASYS System Opens 8/28/06. Abstracts Due by November 22, 2006.

You are invited to submit an abstract for a research presentation at the 233rd National Meeting of the American Chemical Society, to be held March 25-29, 2007 in Chicago, IL. All abstracts should be submitted online using the OASYS system, which will open August 28, 2006 for the Chicago meeting. The deadline for submission of abstracts will be November 22, 2006. This date will also be the deadline for submission of travel grant applications, as outlined above and on page 3 of this Newsletter. Please watch the Division Homepage, located at:

http://www.acsmedchem.org/

for additional information and online abstracts prior to the meeting. For more information on programming or abstract submission, contact the Program Chair, Dave Rotella at rotelld@wyeth.com.

Advertise in the ACSMEDI Newsletter

The ACSMEDI Newsletter is distributed twice a year to 10,500 medicinal and organic chemist members, and is freely accessible to all through the ACSMEDI homepage. In response to a number of inquiries, we have established the following advertising policy, effective with this issue:

One-quarter page: $350.00
One-half page: $500.00
Full page: $900.00

To place an ad or get more information, contact the editor at pwoster@wayne.edu
ACS Division of Medicinal Chemistry Student Travel Grants

APPLICANTS MUST SUBMIT AN ABSTRACT SEPARATELY VIA OASYS SYSTEM
The deadline for Travel Grant applications is the same as the abstract deadline for that meeting

* Name of Applicant for Travel Grant ______________________________________________

* Degree: ___________________________ Year Obtained ______________________________

* Present Institution: ______________________________________________________________

* Department: _____________________________________________________________________

*E-mail Address: __________________________________________________________________

* Work to be reported was (check one or more):
  a. Ph.D. Thesis ______
  b. M.S. Thesis ______
  c. Postdoctoral Fellowship ______

*Supported by (indicate source of support for this work):
  a. Grant ______________
  b. Department ______________
  c. Other ______________

Send the completed application form and a copy of the OASYS abstract to:

David P. Rotella, Ph.D.
Wyeth Research
CN 8000
Princeton, NJ 08543
Phone: 732-274-4504
rotelld@wyeth.com
MEDI Spotlight Papers

Discover the papers MEDI’s expert panel identified as some of the most interesting, significant and/or novel in the MEDI program. Design your schedule at the ACS National Meeting in San Francisco, CA to attend these MEDI presentations.

Sunday

Moscone Convention Center, Room 103
9:00 am  Telomerase inhibition: Overview and perturbation of assemblage. Michael Jarstfer, University of North Carolina
11:30 am  Human telomerase template antagonists as potential anticancer agents. Sergei Gryaznov, Geron Corporation

Moscone Convention Center, Room 102
1:30 pm  Design of bivalent Smac mimetics as highly effective and specific apoptosis inducers in cancer cells. Shaomeng Wang, Comprehensive Cancer Center and the University of Michigan
2:10 pm  Discovery of ABT-737, an inhibitor of Bcl-2 family proteins that promotes apoptosis. Michael D. Wendt, Abbott Laboratories
4:10 pm  A chemical genetics approach for the discovery of activators of apoptosis: From phenotypic cell based HTS assay and structure-activity relationship studies, to identification of potential anticancer agents and molecular targets. Sui Xiong Cai, EpiCept Corporation

Monday

Moscone Convention Center, Room 102
9:00 am  Selectively non-selective drugs (“Magic Shotguns”) vs. selective drugs (“Magic Bullets”) for CNS disorders. Bryan L. Roth, NIH Psychoactive Drug Screening Program and CWRU Medical School
9:35 am  Synthesis, SAR and biological properties of 1-heteroaryl-4-[[u-(1H-indol-3-yl)-alkyl]-piperazines, novel potential antipsychotics combining potent Dopamine D2 receptor antagonism with potent Serotonin reuptake inhibition. Pieter Smid, Solvay Pharmaceuticals
10:10 am  Designing multiple-acting ligands: How hard could that be? Zoran Rankovic, Organon Laboratories Ltd

10:45 am  Tissue targeting with bivalent ligands selective for G protein receptor-coupled heterodimers: Opioid receptors as proof of concept. Philip S. Portoghese, University of Minnesota

Moscone Convention Center, Room 103
9:05 am  Allosteric non-nucleoside inhibitors of HCV RNA polymerase (NS5B). Christopher J. Burns, Viopharma Incorporated
9:45 am  From R1479 to R1626: Optimization of a nucleoside inhibitor of NS5B for the treatment of hepatitis C. David B. Smith, Roche Palo Alto LLC
10:20 am  Discovery and optimization of 3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Rosanna Tedesco, GlaxoSmithKline Pharmaceutical
11:00 am  HepDirect® prodrugs of 2’-methyladenosine for liver-targeted therapy of hepatitis C. Scott J. Hecker, Metabasis Therapeutics, Inc
11:35 am  Challenges toward the discovery of SCH 503034: A potential therapeutic agent for treatment of hepatitis C viral infection. Ashok Arasappan, Schering-Plough Research Institute

Moscone Convention Center, Room 102
1:30 pm  Discovery of viral primases as drug targets: Compound based target elucidation, validation, and advancement to the clinic. J. P. Powers, Amgen Inc
2:10 pm  Stem cell differentiation and small molecule Hedgehog signaling modulators. Xu Wu, Genomics Institute of the Novartis Research Foundation
2:50 pm  Discovery of agonists of the glucose dependent insulinoergic receptor, GPR119, a pancreatic beta-cell oGPCR, for the treatment of NIDDM. Robert M. Jones, Arena Pharmaceuticals
3:30 pm  Estrogen receptor-related receptors α and γ as targets for drug discovery. William J. Zuercher, GlaxoSmithKline
**TUESDAY**

**Moscone Convention Center, Room 102**

- **1:35 pm** Secretases as therapeutic targets in Alzheimer’s disease. **Martin Citron**, Amgen
- **2:05 pm** Cyclic sulfonamides as γ-secretase inhibitors for the treatment of Alzheimer’s disease. **Dmitri Pissarnitski**, Schering-Plough Research Institute
- **2:40 pm** Design and synthesis of potent gamma secretase inhibitors for the disease-modifying treatment of Alzheimer’s Disease. **Boyd Harrison**, Wyeth Research
- **3:15 pm** Structure-based design of potent and highly selective memapsin 2 (BACE) inhibitors. **Arun K. Ghosh**, Purdue University
- **3:50 pm** Design of an efficacious class of BACE inhibitors. **Hsiu-Chiung Yang**, Eli Lilly and Company

**Moscone Convention Center, Room 103**

- **1:50 pm** SAR of the venlafaxine-like scaffold: Discovery of selective norepinephrine reuptake inhibitors. **Paige E. Mahaney**, Wyeth Research
- **2:10 pm** Cyclic guanidine glucagon receptor antagonists for the treatment of type 2 diabetes. **Ronald M. Kim**, Merck and Co., Inc
- **2:30 pm** 2-Aminothiazole: A novel template for the discovery of Dasatinib (BMS-354825), a pan Src/Abl kinase inhibitor. **Jagabandhu Das**, Bristol-Myers Squibb PRL
- **2:50 pm** Discovery and SAR of a boron-containing clinical molecule (AN-2690) for topical onychomycosis treatment. **Yong-Kang Zhang**, Anacor Pharmaceuticals, Inc
- **3:10 pm** Novel, potent and bioavailable CCR5 chemokine receptor small-molecule antagonists for HIV therapy: Scaffold discovery and addressing hERG ion channel affinity in the process of optimizing potency and bioavailability. **Wieslaw Kazmierski**, GlaxoSmithKline
- **3:30 pm** Discovery, synthesis and optimization of a new series of selective HIV integrase inhibitors leading to MK-0518 currently in Phase III clinical trial for treatment of HIV/AIDS. **Vincenzo Summa**, IRBM-MRL Rome
- **3:50 pm** Discovery and optimization of orally bioavailable leukotriene A4 hydrolase inhibitors for the treatment of myocardial infarction. **Vincent Sandanayaka**, deCODE chemistry, Inc
- **4:10 pm** Inhibitors of HCV NS5B polymerase: Synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines. **Daniel P. Larson**, Abbott Laboratories

**WEDNESDAY**

**Moscone Convention Center, Room 102**

- **9:10 am** Novel diketopiperazines as potent and selective oxytocin antagonists. **John Liddle**, GlaxoSmithKline
- **10:30 am** Discovery of novel Bradykinin B1 receptor antagonists for the treatment of pain and inflammation. **Wenyuan Qian**, Amgen
- **11:10 am** Strategies and tactics for lead optimization of melanin concentrating hormone receptor 1 antagonists. **Philip R. Kym**, Abbott Laboratories
- **11:50 am** The discovery of heterocyclic MCH R1 antagonists. **Donald L. Hertzog**, GlaxoSmithKline

**Moscone Convention Center, Room 103**

- **9:00 am** Directed parallel synthesis in lead generation. **Austen Pimm**, AstraZeneca R&D Charnwood
- **9:30 am** Progress in computer-aided drug design. **Julian Tirado-Rives**, Yale University
- **10:30 am** Parallel synthesis and biological evaluation of peptide bond isosteres. **Peter Wipf**, University of Pittsburgh
- **11:00 am** The development of a synthesis machine. **Thomas Lectka**, Johns Hopkins University
- **11:30 am** Computational and informatics support of hit-to-lead investigations. **Yvonne C. Martin**, Abbott Laboratories

**Moscone Convention Center, Room 102**

- **1:35 pm** From “screen to clinic”: Discovery of TRPV1 antagonist SB-705498 for treatment of pain. **Harshad K. Rami**, GlaxoSmithKline Pharmaceuticals

**Moscone Convention Center, Room 103**

- **1:45 pm** New kinase inhibitors for the treatment of hematological malignancies and gastrointestinal stromal tumors. **Paul W. Manley**, Novartis Institutes for BioMedical Research
- **4:05 pm** Design and development of drugs to treat rare vancomycin resistant microbial pathogens. **Ramaiah Muthyala**, University of Minnesota
Gary Grunewald, Ph.D. is Professor of Medicinal Chemistry at the University of Kansas. He obtained undergraduate degrees in both chemistry and pharmacy at Washington State University. His Ph.D. dissertation at the University of Wisconsin contained the first recognized example of the photochemical di-π-methane rearrangement (conversion of barrelen to semibullvalene). He then joined the faculty at the University of Kansas in the Department of Medicinal Chemistry where he has been ever since. He served as department chair from 1994-2003. He received the Higuchi/Simons Research Achievement Award for research excellence in the biomedical sciences at the University of Kansas. His research has concentrated on mechanistic studies of neurotransmitters and drugs affecting them in the central nervous system employing most of the techniques of drug design (conformationally defined (rigid) analogs, QSAR, molecular modeling, site-directed mutagenesis and structure-based drug design using protein crystallography). His group showed, for example, that amphetamine had one optimal conformation for inhibition of the reuptake of catecholamine neurotransmitters but had a different optimal conformation for causing vesicular release of the same neurotransmitter in presynaptic neurons. Recent work has concentrated on finding a potent and selective inhibitor of epinephrine biosynthesis to explore the poorly understood role of epinephrine in the central nervous system. He has served the Medicinal Chemistry Division of ACS as a member of the Long Range Planning Committee (1991-1994), as Vice Chair (1993), Chair (1994) and Councilor (1999-2001). He served as general chair of the 27th National Medicinal Chemistry Symposium in 2000. He is a Fellow of both the AAPS and AAAS.

William J. Greenlee, Ph.D. was born in 1950 in Columbus, OH. He began his career in chemistry as a high school student while working at his father’s company, “Chemical Samples Company“, synthesizing and purifying acetylenes and other hydrocarbons. While an undergraduate at The Ohio State University, Greenlee carried out research with Prof. Paul Gassman on strained ring hydrocarbons. After receiving his B.S. degree in chemistry at OSU in 1972, Greenlee was awarded an NSF Predoctoral Fellowship and began graduate studies with Prof. Robert B. Woodward at Harvard University, receiving his Ph.D. degree in 1976, after completing the first total synthesis of (+/-)marasmic acid. He was an NIH Posdoctoral Fellow at Columbia University with Prof. Gilbert Stork, and was a member of the team that completed the first total synthesis of cytochalasin B. Dr. Greenlee joined Merck Research Laboratories in 1977 as a member of the New Lead Discovery department where he became part of the team under Dr. Arthur Patchett that discovered potent inhibitors of angiotensin-converting enzyme, including enalapril (Vasotec™) and lisinopril (Prinivil™). He and his associates investigated the design and synthesis of inhibitors of enzymes of bacterial cell-wall synthesis (alanine racemase, D-Ala-D-Ala ligase) as potential antibacterial agents, and renin inhibitors for hypertension. Greenlee and his group also worked on angiotensin II receptor antagonists, an effort that evolved into a collaboration with scientists at the Dupont Merck Pharmaceutical Company. Greenlee’s team identified several potent angiotensin AT1 antagonists including MK-996, and developed the first potent dual AT1/AT2 antagonists. His group also discovered potent angiotensin AT1 agonists, the first nonpeptide agonists of a peptide receptor outside the opioid field. He and his associates also developed orally bioavailable endothelin receptor antagonists. He was promoted to Director in 1989 and to Senior Director in 1992. In 1995, Greenlee joined the Schering Plough Research Institute (SPRI) as Senior Director, Cardiovascular and CNS Chemical Research, and is currently Vice President, CNS and Cardiovascular Chemistry and High-Throughput Synthesis. At Schering-Plough, he directs a group of 80 chemists in the design and synthesis of potential drug candidates for treatment of Alzheimer’s disease, obesity,
diabetes, thrombosis and chronic pain. His group has discovered six development candidates that have entered clinical trials.

Greenlee chaired the Medicinal Chemistry Gordon Conference in 1997 and has served as Chair for both the Medicinal Chemistry (2003) and Organic Chemistry (2004) Divisions of the American Chemical Society. He severed as Section Editor (Cardiovascular and Pulmonary), for Annual Reports in Medicinal Chemistry (1999–2004), and is currently Perspectives Editor for the Journal of Medicinal Chemistry. He received the Alfred Burger Award in Medicinal Chemistry from the American Chemical Society in 2004. He is Co-Organizer of the annual Drew Residential School on Medicinal Chemistry, and serves on the Scientific Advisory Board for Rider University in Lawrenceville, NJ. He is author of more than 130 research publications and inventor on over 60 U.S. patents.

William F. Michne, Ph.D. was born in Albany, New York, on December 9, 1942, the youngest of three children. His father was a welder in the repair shops of the New York Central Railroad, and his mother was a part-time waitress. He received a BS in chemistry from Siena College in 1964, and began immediate employment at the Sterling-Winthrop Research Institute as an Assistant Research Chemist. Simultaneously, he began graduate studies in organic chemistry at Rensselaer Polytechnic Institute, earning a doctorate in 1968. His first major achievement was the synthesis of a series of benzomorphanones. These morphine analogs exhibited unusual pharmacological properties, both in vitro and in vivo, relative to all previously studied compounds in this class. While they were very potent in assays for morphine-like behavior, their activity was rather insensitive to reversal by naloxone. Further study of one of these compounds, ketazocine, led to the discovery of the kappa opioid receptor subtype. Ketazocine advanced to human clinical trials for pain. The single enantiomer ethylketazocine, more commonly known as EKC, advanced to preclinical development as an intravenous anesthetic, and was widely used in early studies of the kappa receptor.

The next major phase of his career extended his work on benzomorphans to analogs of the exceedingly potent opiates known as thebaine Diels-Alder adducts. He and his co-workers devised a stereospecific synthesis of a very challenging construct of three contiguous asymmetric centers two of which were adjacent and quaternary. The synthesis was eventually carried out on multi-kilogram scale to support the advancement of three compounds. One of them, tonazocine, was the first non-peptide delta opioid agonist, and was clinically as efficacious as morphine. Over the next decade his career advanced with positions of increasing responsibility. Research groups under his direction had highly focused programs in the areas of pain and inflammation, cardiovascular agents, anti-viral agents, and immunology. These groups produced two compounds in clinical evaluation, an additional three compounds in advanced safety evaluation, a total of 23 patents, 32 publications, and 26 presentations.

The early nineties saw the emergence of high-throughput screening, with the attendant problem of how to sort through the huge amounts of data being generated to find the compounds or series most likely to advance through the development process. He took up this challenge, and with a half dozen or so co-workers developed the objectives necessary to quickly achieve this goal. He published the first description of the Hit-to-Lead process as a stand alone concept in 1996, setting forth the five objectives of Hit-to-Lead that remain valid today, despite the more recent addition of further optional components that can increase the value of this separate phase. During the last five years of active employment, he assumed the position of Senior Principal Scientist at AstraZeneca. Here he began to address fundamental questions of small molecule biological activity and selectivity, work that continues with academic collaborators.

Throughout his career he was very active in the scientific community. As an Associate Professor of Chemistry at the Albany College of Pharmacy he taught medicinal chemistry for 7 years. He served on the editorial advisory board of the Journal of Medicinal Chemistry, and was a section editor for Annual Reports in Medicinal Chemistry. He served on the ACS MEDI Long Range Planning Committee, and has organized several symposia. He was Chair of the 1999 Gordon Conference on Medicinal Chemistry, and Co-Chair of the 2002 National Medicinal Chemistry Symposium. He was also Co-Chair of the Conference on New Chemical Technologies Accelerating Drug Discovery, 2001, and served on the Advisory Board for Hit-to-Lead, World Pharmaceutical Congress, 2004.
Good Leads, Bad Bioavailability?

Successful Lead Optimization is About More Than Efficacy

Meet us at ACS Fall 2006
Booth #513

ACD/Structure Design Suite

Read more at www.acdlabs.com/acsmedchem

Visionary Software  Advancing Research
2006 Medicinal Chemistry Award To George Ellestad

George A. Ellestad, Adjunct Senior Research Scientist in the Department of Chemistry at Columbia University, has been presented with the Medicinal Chemistry Award by the ACS Division of Medicinal Chemistry. The award was given on June 28 during the 30th National Medicinal Chemistry Symposium in Seattle. Ellestad spent most of his career at Lederle Laboratories in Pearl River, N.Y., which later became Wyeth Pharmaceuticals. One of his primary contributions was the unraveling of the DNA cleavage chemistry and mechanism of action of the potent enediyne-containing antitumor agent calicheamicin. His work on the structure and bioorganic chemistry of calicheamicin contributed to the development of Mylotarg for the treatment of relapsed myeloid leukemia. Ellestad was also involved in the search for a new tetracycline that led to the antibiotic Tigecycline. Ellestad retired from Wyeth in 2004. His current research focuses on porphyrin-conjugated DNA to increase circular dichroism sensitivity for monitoring DNA conformational changes.

Paul Hergenrother Receives 2006 David W. Robertson Award

The Division is pleased to announce that Professor Paul Hergenrother is the recipient of the 2006 David W. Robertson Award for Excellence in Medicinal Chemistry. Paul obtained his B.S. in Chemistry from the University of Notre Dame in 1994, and his PhD in Chemistry under the direction of Professor Stephen F. Martin in 1999. His dissertation work encompassed two distinct projects in the areas of biochemistry and organic synthesis: the elucidation of the catalytic mechanism of the enzyme phospholipase C, and the total synthesis of the antibiotic erythromycin B. He was a co-author on 14 publications during his graduate career, and was awarded an ACS graduate student fellowship from the Division of Organic Chemistry. In 1999 he moved as an American Cancer Society postdoctoral fellow to the laboratory of Professor Stuart L. Schreiber in the Department of Chemistry and Chemical Biology at Harvard University, and in 2001 he joined the faculty at the University of Illinois, Urbana-Champaign.

Paul’s laboratory is using small molecules to identify novel targets for the treatment of cancer, neurodegeneration, and drug-resistant bacteria. In 2004, his laboratory reported a small molecule that causes elimination of the genes encoding resistance-mediating proteins, thus re-sensitizing bacteria to standard antibiotics. His laboratory has also identified interesting compounds with potent activity against melanoma, colon cancer, and lung cancer, in addition to devising novel RNA binding ligands. Paul has twice been named to the “List of Teachers Ranked as Excellent by Their Students” at the University of Illinois, an honor accorded to approximately the top 10% of teachers on campus. He has also received several awards, most notably the NSF Career Award, the Beckman Young Investigator Award, a Sloan Foundation Fellowship, the GlaxoSmithKline Chemistry Scholar Award and the Camille Dreyfus Teacher-Scholar Award. He was recently named a top innovator under age 35 by Technology Review magazine. Professor Hergenrother will be honored at an award symposium organized by the Division of Medicinal Chemistry at the 2006 Fall National Meeting of the American Chemical Society.
Division Leaders Meet to Develop MEDI Strategic Plan

The ACSMEDI Executive Committee met at Wayne State University in Detroit, MI on June 10-12, 2006 to begin to develop a strategic plan for the Division. Strategic planning was conducted using the Touchstone Associates 5 Conversations model as presented at the 2005 ACS Strategic Planning Training Session (Current State, Case for Change, Future State, Strategy and Barriers). Prior to the meeting, prominent members of the medicinal chemistry community were asked for their input and opinions, and members of the Executive Committee also completed a pre-meeting questionnaire. Participants worked together to develop the following vision statement:

The Division is a global authority and advocate for the practice of medicinal chemistry with the goal of improving human health through drug discovery research and education.

The strengths, weaknesses, opportunities and threats to the Division and its programs were discussed, followed by the identification of four key initiatives to be pursued over the following 3 years:

1. Provide, support and advocate education in medicinal chemistry
2. Be a strong advocate for interdisciplinary, cutting edge research as reflected in our programming, policy and global outreach
3. Increase opportunities for member participation and involvement in Division affairs
4. Enhance communication (Pat Woster) by targeting the membership, other scientists, policy makers and the public.

Subcommittees comprised of members of the Executive Committee were formed to address each of these initiatives, and each group was charged with recruiting Division members for committee service. If you are interested in serving on any of the four committees listed above, contact Pat Woster at pwoster@wayne.edu, or Rich Gibbs at rag@pharmacy.purdue.edu.

Award to be Created to Honor Dr. Robert M. Scarborough

The ACS Division of Medicinal Chemistry plans to establish an award in memory of Robert Scarborough, sponsored by Portola Pharmaceuticals. Robert M. Scarborough, Jr., 52, Sr. V. P. of Medicinal Chemistry at Portola Pharmaceuticals, Inc. in South San Francisco, CA, died on June 25 from the complications of a brain tumor. Bob Scarborough was born near Philadelphia on November 27, 1953, and received his B. S. degree at the Philadelphia College of Textiles and Science (1975), He then earned a Ph. D. in organic chemistry at the University of Pennsylvania (1979), working with Professor Amos B. Smith III. Thereafter he completed a postdoctoral fellowship with Professor Paul Bartlett at University of California, Berkley. Among Bob’s most important contributions are the discovery of two major cardiovascular drugs - nesiritide (Natrecor®, Scios, and Johnson & Johnson) and eptifibatide (Integrilin®, Millennium Pharmaceuticals, Schering Plough, and GlaxoSmithKline). In 2003, Dr. Scarborough co-founded Portola Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel drugs for the prevention and treatment of cardiovascular disease, where he held the position of Senior Vice President, Medicinal Chemistry, until his death. His longtime colleague and Senior Vice President of Biology at Portola Pharmaceuticals, Inc. David Phillips, describes Scarborough as one of the most accomplished medicinal chemists of his generation, discovering nesiritide while working at California Biotechnology and eptifibatide while working at COR Therapeutics, Inc. Over a career that spanned more than 25 years, in addition to the two approved drugs, three additional drugs resulted from the efforts of Scarborough and his team and are currently in clinical trials at various stages of development. Donations or inquiries concerning the "The Robert M Scarborough Excellence in Medicinal Chemistry Award" can be addressed to Scarboroughfund@portola.com.
Coming soon to Organic Synthesis Labs everywhere!

We’re getting ready to release our new Medicinal Chemistry - Reagents for Organic Synthesis product guide and we’d like you to have a copy. Stop by our booth at the Fall ACS Show (#832/834) and we’ll be glad to give you one! Or you can request a copy by calling 800-222-0342 or visiting the following link on our website: www.emdchemicals.com/analytics/MedicinalChemistry

And remember, we back all of our products with some of the best sales, technical and customer service in the business.

www.emdchemicals.com
NIH RO1 Funding Opportunity PAS-06-066


The purpose of this PAS is to support research for the design, synthesis and pharmacological evaluation of new classes of compounds as potential treatment agents for cocaine, methamphetamine or cannabinoid addiction based on novel pharmacological interventions and molecular targets other than biogenic amine transporters. The ultimate goal of this initiative is to expand existing research scope and elicit research proposals that will identify new pharmacotherapy based on current and advanced molecular and neurobiological understanding of the pathology of drug addiction and its relapse in the brain. NIDA intends to commit a total of $3 million in FY 2006 to this Program Announcement with set-aside funds (PAS). Approximately 10 new awards will be made. The total amount awarded and the number of awards will depend upon the duration and costs of the applications received, and are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.

Division Selects 2006-2007 Predoctoral Fellows

Each year, the ACS Division of Medicinal Chemistry awards seven $24,000 Predoctoral Fellowships to graduate students in their 3rd or 4th year of study. These fellowships are supported through the generosity of seven benefactors from the Pharmaceutical industry (Sanofi-Aventis, Novartis, Eli Lilly, Bristol-Myers Squibb, Amgen, Wyeth and Pfizer). To be selected, students must be engaged in medicinal chemistry research in a Medicinal Chemistry, Pharmaceutical Chemistry, Biochemistry, or Chemistry department listed in the current ACS Directory of Graduate Research. We are pleased to announce the winners of this year’s competition, who will begin their Fellowships during the 2006-2007 academic year. Complete info on this year’s fellows, including pictures and bios, can be found on the Division RSS feed (see above) or the Division WWW page at http://www.acsmedchem.org

Congratulations to all of the awardees and their advisors for this outstanding achievement:


Omid Khakshoor, University of California-Irvine (Advisor: James S. Nowick). Sponsored by Novartis.

Benjamin Leslie, University of Illinois Urbana-Champaign (Advisor: Paul Hergenrother). Sponsored by Eli Lilly.

Andrew Patterson, University of California at Berkeley (Advisor: Jonathan Ellman). Sponsored by Bristol-Myers Squibb.


Pauline Wyrembak, Yale University (Advisor: Andrew Hamilton). Sponsored by Pfizer.

Division News Now Available in RSS Format

ACSMEDI news and announcements are now posted periodically on the Division RSS feed. RSS (Really Simple Syndication) continually delivers the latest news directly to your reader (also known as a News Aggregator). RSS feeds have an URL just like a web page, except that they end in .rss or .xml. They are marked on most web pages with a red logo that either says XML or RSS. There are a variety of news readers that can be downloaded for free. Each time you start your news reader, the list for each of your subscriptions is updated automatically for continual access to the latest news. sports and technology. When you visit a web page, look for the red icon to get the RSS address.

Members are encouraged to utilize this technology to receive Division news. This will help us minimize the number of emails sent out by the Division. For more information on using the Division RSS feed, go to the Division WWW page at http://www.acsmedchem.org and follow the appropriate links.
*****How to Change Your Contact Information and E-Mail Address*****

Division officers do not have the capability or authority to change member contact information, including E-mail addresses. All mailing lists used by the Division are generated by the ACS National office, and are used as supplied. Members can change their contact information by registering at http://www.chemistry.org, logging in, and selecting “Edit My Profile”. You will need your ACS membership number during this process. The mailing lists supplied to the Division are updated quarterly, and all subsequent snail mail and E-Mail will be sent to the addresses you specify. Members are encouraged to check the accuracy of their contact information to ensure the receipt of all future Division mailings and electronic messages. A correct E-mail address is essential, since the Division has moved to an almost exclusively electronic format.

---

Austrian German_Hungarian_Italian_Polish_Slovenian 5th Joint Meeting on Medicinal Chemistry, June 17-21, 2007, Portorož, Slovenia

The Organizing Committee cordially invites you to attend the Austrian-German-Hungarian-Italian-Polish-Slovenian Joint Meeting on Medicinal Chemistry to be held in Portorož, Slovenia, June 17-21, 2007, under the auspices of the European Federation for Medicinal Chemistry. The 5th Joint Meeting on Medicinal Chemistry, which will be organized by the Medicinal Chemistry Section of the Slovenian Pharmaceutical Society, will continue the tradition of previous joint meetings held in Taormina, Italy (1999), Budapest, Hungary (2001), Krakow, Poland (2003), and Vienna, Austria (2005). The meeting will focus on important new developments in medicinal chemistry and seek to create an atmosphere for in-depth discussions in all disciplines of drug discovery and drug development process. A flyer in PDF format is available on the Division RSS feed. All potential participants interested in receiving updated information are invited to register at http://www.jmmc2007.si. We look forward to meeting you on the beautiful Adriatic coast.

Danijel Kikelj, Symposium Chairman  E-mail: jmmc2007@ffa.uni-lj.si

---

Annual Reports in Medicinal Chemistry Now Available On-Line

Annual Reports in Medicinal Chemistry is now available on-line back to Volume 35, and is searchable by topic, author, etc., or by browsing individual volumes. You must register with Elsevier prior to using this on-line resource. To register, activate access and to create your personal account, you will need your American Chemical Society Membership number. If you do not know your society membership number please contact the ACS at service@acs.org. The Membership Number has to be entered at:

https://cs.sciencedirect.com/activate/armc/members

If there are zeroes at the beginning of your ACS number, leave them out when you enter it. Note that “https://” MUST be entered for this URL – “http://” will not work. This is to ensure that your registration details are secured when you enter them into the registration form. After entering, click on "submit". The next step is completing a user profile. You will be asked to fill out a form and choose a password. A username will be assigned. Both username and password will be case sensitive. After registration you can directly login with your new username and password. Note - please do NOT use special characters, such as ö, â, æ when entering your personal details into the profile form. In the future (after you register) you can go straight to http://www.sciencedirect.com/armc and enter your personal username and password in the login bar on the top of the page. If you encounter any problems registering, please note that older browsers may not support SSL encryption, which is required for secure data transmission. Also, cookies must be enabled in your browser to support the registration process. Should you require any assistance, you will find Customer Support contact information on the Division web page.
Fragments of Life™

More than a fragment screening library, it’s intelligent lead identification.

With the increasing popularity of fragment screening to identify lead compounds, deCODE chemistry & biostructures has developed the Fragments of Life™ approach to lead identification. Our fragment-based approach is built on the principle that proteins have evolved to bind small molecules, such as metabolites, and other proteins within the cell. By combining this natural binding affinity with desirable pharmaceutical properties, our researchers have assembled a library of over 800 small molecules with the following characteristics:

- Ability to bind active sites and potentially unknown allosteric sites
- High information content per atom
- High water soluble
- Effective and amenable foundation for subsequent medicinal chemistry efforts

The Fragments of Life™ is a dynamic technology. Our screening collection is continually growing and evolving, and may be enriched with new fragments tailored to your specific target.

Lead identification is just the beginning. deCODE offers a complete range of drug discovery and development services that can efficiently advance Fragments of Life™ leads from initial hits through drug candidate refinement to clinical development.
ACS Division of Medicinal Chemistry
Executive Committee 2006

1. Regular Executive Committee Members

Chair 2006
Richard A. Gibbs, Ph.D.
Heine Pharmacy Bldg, 575 Stadium Mall Dr.
Purdue University
West Lafayette, IN 47907-2091
Phone: 765-494-1456
rag@pharmacy.purdue.edu

Vice Chair 2006
James R. McCarthy, Ph.D.
Drop Code 1920
1 Lilly Corporate Center
Indianapolis, IN 46285-0002
(317) 433-1345
jmccarthy@lilly.com

Program Chair 2005-2006
David P. Rotella, Ph.D.
Wyeth Research
CN 8000
Princeton NJ, 08543
Phone: 732-274-4504
rotelld@wyeth.com

Secretary and Public Relations 2005-2007
Patrick M. Woster, Ph.D.
3132 Applebaum Hall
Wayne State University
Detroit, MI 48202
Voice: (313)-577-1523
pwoster@wayne.edu

Membership Chair
Yanping Xu, Ph.D.
Lilly Research Laboratories
Lilly Corporate Center
DC 1910
Indianapolis, IN 46285
Tel: (317) 433-1113
xu_yanping@lilly.com

Treasurer 2006-2008
Danny L. Lattin, Ph.D.
4950 Research Park Way
Lawrence, KS 66047
Voice: (785) 843-3460
lattind@ku.edu

Academic Councilor 2005-2007
Jeffrey Aubé, Ph.D.,
Department of Medicinal Chemistry
School of Pharmacy, The University of Kansas
1251 Wescoe Hall Drive, Room 4070
Lawrence, Kansas 66045-2506
Phone: 785-864-4496
jaube@ku.edu

Academic Councilor 2006-2008
Gunda I. Georg, Ph.D.
Department of Medicinal Chemistry
School of Pharmacy, The University of Kansas
1251 Wescoe Hall Drive, Room 4070
Lawrence, Kansas 66045-2506
Phone: 785-864-4498
georg@ku.edu

Industrial Councilor 2004-2006
James Monn, Ph.D.
Eli Lilly and Co.
Drop Code 0510, Bldg. 48, C1109
Indianapolis, IN 46285
317-276-9101
monn_james_a@lilly.com

Industrial Councilor 2006-2008
Peter R. Bernstein, Ph.D.
Department of Chemistry
AstraZeneca Pharmaceuticals
1800 Concord Pike
Wilmington, DE 19803
Phone: 302-886-8966
peter.bernstein@astrazeneca.com

Past Chair 2006
Daniel Flynn, Ph.D.
Deciphera Pharmaceuticals, LLC
4950 Research Park Way
Lawrence, KS 66047 USA
(785) 838-3767
dflynn@deciphera.com
2. Alternate Councilors and Members-at-Large (Ad Hoc EC Members)

Academic Alternate Councilor 2006-2008
Kenneth A. Jacobson, Ph.D.
NIH, 8 Center Drive
MSC 0810, Building 8A, Room B1A-17
Bethesda, MD 20892,
(301) 496-9024
kajacobs@helix.nih.gov

Academic Alternate Councilor 2005-2007
Kenneth Kirk, Ph.D.
Laboratory of Bioorganic Chemistry
NIDDK, National Institutes of Health
Building 8A, Room B1A-02
8 Center Drive, MSC 0810
Bethesda, MD 20892-0810
301-496-2619
kennethk@bdg8.niddk.nih.gov

Industrial Alternate Councilor 2004-2006
Joel C. Barrish, Ph.D.
P.O. Box 4000, Mailbox L12-06
Princeton, New Jersey 08543
Phone (609) 252-5897
joel.barrish@bms.com

Industrial Alternate Councilor 2006-2008
Jill A. Panetta, Ph.D.
Chief Scientific Officer
Innocentive
Intech Park 11, Suite 300
6625 Network Way
Indianapolis, IN 46278-1683
Voice: 317-276-5793
jpanetta@innocentive.com

EFMC Liaison (Ad Hoc) 2006
Thomas J. Perun, Ph.D.
47731 Old Houston Hwy
Hempstead, TX 77445
tjperun@aol.com

Member-at-Large (Ad Hoc) 2006-2007
Jeff Zablocki, Ph.D.
CV Therapeutics, Inc.
3172 Porter Drive
Palo Alto, CA 94304
650-384-8547
jeff.zablocki@cvt.com

Member-at-Large (Ad Hoc) 2006-2007
Carston R. (Rick) Wagner
Dept. of Medicinal Chemistry
308 Harvard St. S.E.
8-106 Weaver-Densford Hall
College of Pharmacy
University of Minnesota
Minneapolis, MN 55455
Phone: (612) 625-2614
FAX: (612) 624-0129
wagne003@tc.umn.edu
2006 Division of Medicinal Chemistry Long Range Planning Committee

James R. McCarthy, Ph.D.
Committee Chair 2006
Drop Code 1513
1 Lilly Corporate Center
Indianapolis, IN 46285-0002
(317) 433-1345
mccarthy_james@lilly.com

Scott Larsen (2005-2007)
Pfizer Global R&D
2800 Plymouth Road
Ann Arbor, MI 48105
Phone: 734-622-2535
Scott.d.Larsen@pfizer.com

Boyd Harrison (2004-2006)
Director, Wyeth Research
CN8000, Princeton, NJ 08543
Phone: 732-274-4104
Fax: 732-274-4129
harrisb3@wyeth.com

Jeff Zablocki (2005-2007)
CV Therapeutics, Inc.
3172 Porter Drive
Palo Alto, CA 94304
650-384-8547
jeff.zablocki@cvt.com

Andrew Stamford (2004-2006)
Schering Plough Research Institute
K15-2545
2015 Galloping Hill Road
Kenilworth NJ, 07033
Phone: 908-740-3481
Fax: 908-740-7152
Andrew.Stamford@spcorp.com

Brian Blagg (2005-2007)
Department of Medicinal Chemistry
Malott Hall
The University of Kansas
Lawrence, KS 66045
785 864 2288
bblagg@ku.edu

Distinguished Prof. and Director
Institute of Chemical Biology & Drug Discovery (ICB&DD)
The Chemistry Building
SUNY-Stony Brook
Stony Brook, NY 11794-3400
Phone: (631) 632-7947 or 1311
Fax: (631) 632-7942
iojima@notes.cc.sunysb.edu

Roland Dolle (2005-2007)
Adolor Corporation
Department of Chemistry
Exton, PA 019341
Tel 484-595-1024
rdolle@adolor.com

Peter Wipf (2004-2006)
Department of Chemistry
University of Pittsburgh
Chevron Science Center
219 Parkman Avenue
Pittsburgh, PA 15260
Phone: 412-624-8606
Fax: 412-624-0787
pwipf@pitt.edu

Paul J. Hergenrother (2005-2007)
Asst. Professor of Chemistry
University of Illinois
Department of Chemistry Box 36-5
270 Roger Adams Lab
600 S. Mathews
Urbana, IL 61801
hergenro@uiuc.edu
We need your input! Send your suggestions for symposia for MEDI scientific programming at national ACS meetings to one of the members of the EC or Long Range Planning Committee